ATE267168T1 - Beta-alanin-derivate als zell-adhäsions- inhibitoren - Google Patents
Beta-alanin-derivate als zell-adhäsions- inhibitorenInfo
- Publication number
- ATE267168T1 ATE267168T1 AT98959547T AT98959547T ATE267168T1 AT E267168 T1 ATE267168 T1 AT E267168T1 AT 98959547 T AT98959547 T AT 98959547T AT 98959547 T AT98959547 T AT 98959547T AT E267168 T1 ATE267168 T1 AT E267168T1
- Authority
- AT
- Austria
- Prior art keywords
- beta
- cell adhesion
- alanine derivatives
- adhesion inhibitors
- cell
- Prior art date
Links
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical class NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 title abstract 2
- 230000021164 cell adhesion Effects 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000017455 cell-cell adhesion Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6648497P | 1997-11-24 | 1997-11-24 | |
| GBGB9727215.7A GB9727215D0 (en) | 1997-12-23 | 1997-12-23 | Substituted beta-alanine derivatives as cell adhesion inhibitors |
| PCT/US1998/024898 WO1999026921A1 (en) | 1997-11-24 | 1998-11-24 | SUBSTITUTED β-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE267168T1 true ATE267168T1 (de) | 2004-06-15 |
Family
ID=26312837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98959547T ATE267168T1 (de) | 1997-11-24 | 1998-11-24 | Beta-alanin-derivate als zell-adhäsions- inhibitoren |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1034164B1 (de) |
| JP (1) | JP2001524465A (de) |
| AT (1) | ATE267168T1 (de) |
| AU (1) | AU751950B2 (de) |
| CA (1) | CA2309341A1 (de) |
| DE (1) | DE69824037T2 (de) |
| ES (1) | ES2221227T3 (de) |
| WO (1) | WO1999026921A1 (de) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT991619E (pt) | 1997-06-23 | 2004-02-27 | Upjohn Co | Inibidores da adesao celular mediada pela alfa4beta1 |
| MY153569A (en) | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
| GB9805655D0 (en) | 1998-03-16 | 1998-05-13 | Celltech Therapeutics Ltd | Chemical compounds |
| US6521626B1 (en) | 1998-03-24 | 2003-02-18 | Celltech R&D Limited | Thiocarboxamide derivatives |
| US6685617B1 (en) | 1998-06-23 | 2004-02-03 | Pharmacia & Upjohn Company | Inhibitors of α4β1 mediated cell adhesion |
| GB9814414D0 (en) | 1998-07-03 | 1998-09-02 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9821061D0 (en) | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9826174D0 (en) | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
| US6518283B1 (en) | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
| DK1265606T3 (da) | 1999-08-13 | 2007-02-12 | Biogen Idec Inc | Celleadhæsionsinhibitorer |
| US6534513B1 (en) | 1999-09-29 | 2003-03-18 | Celltech R&D Limited | Phenylalkanoic acid derivatives |
| USRE39921E1 (en) | 1999-10-07 | 2007-11-13 | Smithkline Beecham Corporation | Chemical compounds |
| GB9923748D0 (en) | 1999-10-07 | 1999-12-08 | Glaxo Group Ltd | Chemical compounds |
| US6388084B1 (en) | 1999-12-06 | 2002-05-14 | Hoffmann-La Roche Inc. | 4-pyridinyl-n-acyl-l-phenylalanines |
| US6380387B1 (en) | 1999-12-06 | 2002-04-30 | Hoffmann-La Roche Inc. | 4-Pyrimidinyl-n-acyl-l phenylalanines |
| US6455539B2 (en) | 1999-12-23 | 2002-09-24 | Celltech R&D Limited | Squaric acid derivates |
| AP2002002565A0 (en) | 1999-12-28 | 2002-06-30 | Pfizer Prod Inc | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases. |
| AU2001233069A1 (en) * | 2000-01-28 | 2001-08-07 | Biogen, Inc. | Pharmaceutical compositions containing anti-beta 1 integrin compounds and uses |
| WO2001079173A2 (en) | 2000-04-17 | 2001-10-25 | Celltech R & D Limited | Enamine derivatives as cell adhesion molecules |
| US7393652B2 (en) | 2000-05-10 | 2008-07-01 | The Trustees Of Columbia University In The City Of New York | Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2) |
| US7312044B2 (en) | 2003-03-07 | 2007-12-25 | The Trustees Of Columbia University In The City Of New York | Type 1 ryanodine receptor-based methods |
| US6545013B2 (en) | 2000-05-30 | 2003-04-08 | Celltech R&D Limited | 2,7-naphthyridine derivatives |
| US6403608B1 (en) | 2000-05-30 | 2002-06-11 | Celltech R&D, Ltd. | 3-Substituted isoquinolin-1-yl derivatives |
| EP1301488A1 (de) | 2000-07-07 | 2003-04-16 | Celltech R&D Limited | Bicyclische heteroaromatische ring enthaltende quadratsäure-derivate als integrin-antagonisten |
| EP1305291A1 (de) | 2000-08-02 | 2003-05-02 | Celltech R&D Limited | 3-substituierte isochinolin-1-yl-derivate |
| US6486174B2 (en) | 2000-08-07 | 2002-11-26 | 3-Dimensional Pharmaceuticals, Inc. | Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists |
| US20020037897A1 (en) * | 2000-08-07 | 2002-03-28 | 3-Dimensional Pharmaceuticals, Inc. | Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists |
| DE10041428A1 (de) * | 2000-08-23 | 2002-03-07 | Merck Patent Gmbh | Biphenylderivate |
| DE10041423A1 (de) * | 2000-08-23 | 2002-03-07 | Merck Patent Gmbh | Biphenylderivate |
| MY129000A (en) | 2000-08-31 | 2007-03-30 | Tanabe Seiyaku Co | INHIBITORS OF a4 MEDIATED CELL ADHESION |
| GB0025354D0 (en) | 2000-10-17 | 2000-11-29 | Glaxo Group Ltd | Chemical compounds |
| US6376514B1 (en) | 2000-10-17 | 2002-04-23 | The Procter & Gamble Co. | Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof |
| US6693099B2 (en) | 2000-10-17 | 2004-02-17 | The Procter & Gamble Company | Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance |
| ES2200617B1 (es) | 2001-01-19 | 2005-05-01 | Almirall Prodesfarma, S.A. | Derivados de urea como antagonistas de integrinas alfa 4. |
| US7482365B2 (en) | 2002-02-08 | 2009-01-27 | Glaxo Group Limited | Piperidylcarboxamide derivatives and their use in the treatment of tachykinin-mediated diseases |
| GB0203020D0 (en) | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
| GB0203022D0 (en) | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
| WO2003074478A1 (en) * | 2002-03-05 | 2003-09-12 | Sumitomo Chemical Company, Limited | Process for the preparation of biaryl compounds |
| DE10228132A1 (de) * | 2002-06-24 | 2004-01-22 | Arzneimittelwerk Dresden Gmbh | Amide cyclischer Aminosäuren als PDE 4 Inhibitoren |
| ES2399047T3 (es) * | 2002-09-20 | 2013-03-25 | Merck Serono Sa | Derivados de piperazina y procedimiento de uso |
| US7544678B2 (en) | 2002-11-05 | 2009-06-09 | The Trustees Of Columbia University In The City Of New York | Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) |
| US8710045B2 (en) | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
| FR2869904B1 (fr) * | 2004-05-07 | 2006-07-28 | Fournier S A Sa Lab | Modulateurs des recepteurs lxr |
| US7196112B2 (en) | 2004-07-16 | 2007-03-27 | Biogen Idec Ma Inc. | Cell adhesion inhibitors |
| US8017612B2 (en) * | 2006-04-18 | 2011-09-13 | Japan Tobacco Inc. | Piperazine compound and use thereof as a HCV polymerase inhibitor |
| AU2008219007A1 (en) | 2007-02-20 | 2008-08-28 | Merrimack Pharmaceuticals, Inc. | Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist |
| ES2525065T3 (es) | 2008-04-11 | 2014-12-17 | Merrimack Pharmaceuticals, Inc. | Ligadores de seroalbúmina humana y sus conjugados |
| CA2763572C (en) | 2009-05-28 | 2017-10-17 | Novartis Ag | Substituted aminopropionic derivatives as neprilysin inhibitors |
| MA33364B1 (fr) | 2009-05-28 | 2012-06-01 | Novartis Ag | Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine |
| WO2010141805A1 (en) * | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Heterocyclic amides as modulators of trpa1 |
| JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
| JP2015520136A (ja) * | 2012-04-25 | 2015-07-16 | コリア リサーチ インスティチュート オブ ケミカル テクノロジーＫｏｒｅａ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｃｈｅｍｉｃａｌｔｅｃｈｎｏｌｏｇｙ | 新規なベータアラニン誘導体、薬学的に許容される塩、及びそれを有効成分として含有する医薬組成物 |
| CN104854086B (zh) * | 2012-12-18 | 2017-06-27 | Ea制药株式会社 | 杂环酰胺衍生物和含有其的药物 |
| WO2014126979A1 (en) | 2013-02-14 | 2014-08-21 | Novartis Ag | Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors |
| AU2014216417B2 (en) | 2013-02-14 | 2016-05-12 | Novartis Ag | Substituted bisphenyl butanoic acid derivatives as NEP inhibitors with improved in vivo efficacy |
| EP2774919A1 (de) * | 2013-03-06 | 2014-09-10 | Pharmeste S.R.L. In Liquidazione | Neuartige Sulfonamid-TRPA1-Rezeptorantagnonisten |
| US20160151275A1 (en) * | 2014-06-16 | 2016-06-02 | James Kevin Shurtleff | Method and devices for manufacturing and delivering of aerosolized formulations |
| MX385777B (es) * | 2014-12-24 | 2025-03-04 | Lg Chemical Ltd | Derivado de biarilo como agonista de gpr120. |
| AU2019373242B2 (en) | 2018-10-30 | 2023-07-13 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
| AU2019373240B2 (en) | 2018-10-30 | 2023-04-20 | Gilead Sciences, Inc. | Quinoline derivatives as alpha4beta7 integrin inhibitors |
| AU2019373244B2 (en) | 2018-10-30 | 2022-05-26 | Gilead Sciences, Inc. | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
| WO2020092401A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN |
| AU2020329207B2 (en) | 2019-08-14 | 2024-02-29 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
| PT4045039T (pt) * | 2019-10-16 | 2025-07-02 | Morphic Therapeutic Inc | Inibição da integrina humana alfa4beta7 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8812597D0 (en) * | 1988-05-27 | 1988-06-29 | Pfizer Ltd | Therapeutic agents |
| US5439930A (en) * | 1992-04-14 | 1995-08-08 | Russian-American Institute For New Drug Development | Biologically active n-acylprolydipeptides having antiamnestic, antihypoxic and anorexigenic effects |
| EP0618223A3 (de) * | 1993-03-08 | 1996-06-12 | Sandoz Ltd | Peptide, die Freisetzung vom Interleukin 1-Bêta, nützlich als entzündungshemmende Wirkstoffe. |
| JPH07138221A (ja) * | 1993-11-11 | 1995-05-30 | Fujisawa Pharmaceut Co Ltd | アミジノ化合物 |
| US5716929A (en) * | 1994-06-17 | 1998-02-10 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| GB2292149A (en) * | 1994-08-09 | 1996-02-14 | Ferring Res Ltd | Peptide inhibitors of pro-interleukin-1beta converting enzyme |
| DE4445500A1 (de) * | 1994-12-20 | 1996-06-27 | Kolbeck Winfried Dr | Verfahren zur Herstellung von [1,4]-Benzodiazepindionen, insbesondere Aza-cycloalkyl-[1,4]-benzodiazepin-dionen aus N·alpha·-(2-Aminoaroyl)-Peptiden und Verwendung der durch dieses Verfahren erhältlichen Verbindungen in Screening-Methoden nach therapeutisch verwendbaren Verbindungen |
| US6306840B1 (en) * | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
| US6248713B1 (en) * | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
| GB9518553D0 (en) * | 1995-09-11 | 1995-11-08 | Fujisawa Pharmaceutical Co | New urea derivatives processes for the preparation thereof and pharmaceutical composition comprising the same |
| WO1997020856A1 (en) * | 1995-12-01 | 1997-06-12 | Hoechst Marion Roussel, Inc. | ACYLATED ENOL DERIVATIVES OF α-KETOESTERS AND α-KETOAMIDES |
| CA2261848C (en) * | 1996-07-25 | 2006-10-24 | Biogen, Inc. | Cell adhesion inhibitors |
| JP4144811B2 (ja) * | 1997-04-18 | 2008-09-03 | セフアロン・インコーポレーテツド | ペプチジル−２−アミノ−１−ヒドロキシアルカンスルホン酸システインプロテアーゼインヒビター |
| CA2291778A1 (en) * | 1997-05-29 | 1998-12-03 | Merck & Co., Inc. | Heterocyclic amide compounds as cell adhesion inhibitors |
| WO1999006437A1 (en) * | 1997-07-31 | 1999-02-11 | Elan Pharmaceuticals Inc. | Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4 |
| PL338373A1 (en) * | 1997-07-31 | 2000-10-23 | Elan Pharm Inc | Dipeptide and its affinite compounds inhibiting adhesion of leucocytes occurring through mediation of vla-4 |
| JPH11292840A (ja) * | 1998-04-06 | 1999-10-26 | Soyaku Gijutsu Kenkyusho:Kk | ノルスタチン誘導体又はその塩 |
| MXPA00011774A (es) * | 1998-05-28 | 2002-10-17 | Biogen Inc | Un nuevo inhibidor vla-4: ome pupa-v. |
-
1998
- 1998-11-24 WO PCT/US1998/024898 patent/WO1999026921A1/en not_active Ceased
- 1998-11-24 AU AU15327/99A patent/AU751950B2/en not_active Ceased
- 1998-11-24 AT AT98959547T patent/ATE267168T1/de not_active IP Right Cessation
- 1998-11-24 CA CA002309341A patent/CA2309341A1/en not_active Abandoned
- 1998-11-24 DE DE69824037T patent/DE69824037T2/de not_active Expired - Fee Related
- 1998-11-24 JP JP2000522079A patent/JP2001524465A/ja not_active Withdrawn
- 1998-11-24 EP EP98959547A patent/EP1034164B1/de not_active Expired - Lifetime
- 1998-11-24 ES ES98959547T patent/ES2221227T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE69824037T2 (de) | 2005-06-02 |
| EP1034164A4 (de) | 2001-07-11 |
| AU751950B2 (en) | 2002-09-05 |
| JP2001524465A (ja) | 2001-12-04 |
| CA2309341A1 (en) | 1999-06-03 |
| ES2221227T3 (es) | 2004-12-16 |
| EP1034164A1 (de) | 2000-09-13 |
| EP1034164B1 (de) | 2004-05-19 |
| WO1999026921A1 (en) | 1999-06-03 |
| DE69824037D1 (de) | 2004-06-24 |
| AU1532799A (en) | 1999-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69824037D1 (de) | Beta-alanin-derivate als zell-adhäsions-inhibitoren | |
| ATE318841T1 (de) | Biarylalkansäuren in der verwendung als zelladhäsionsinhibitoren | |
| SG158733A1 (en) | Cell adhesion inhibitors | |
| BR9910864A (pt) | Compostos anti-inflamatórios para inibição de aderência celular | |
| DK1053239T3 (da) | Gluccocorticoid-selektive, anti-inflammatoriske midler | |
| EA200100103A1 (ru) | Ингибиторы адгезии клеток | |
| NO20025601L (no) | Arylmetylaminderivater for anvendelse som tryptaseinhibitorer | |
| FI973087A0 (fi) | Soluadheesion inhibiittoreita | |
| EA200100732A1 (ru) | Противовоспалительные и иммуносупрессорные соединения, ингибирующие клеточную адгезию | |
| HUP0302922A3 (en) | Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation and pharmaceutical compositions containing them | |
| CA2186511A1 (en) | Pyrimidinyl derivatives as interleukin inhibitors | |
| BR0008922A (pt) | Compostos úteis como agentes antiinflamatórios | |
| NZ516562A (en) | Pyrimidine-2,4,6-trione metalloproteinase inhibitors | |
| NO20032254D0 (no) | Forbindelser for inhibering av ekspresjon av VACM-I | |
| BR9916746A (pt) | Compostos anti-inflamatórios que inibem adesão de célula | |
| DK1053240T3 (da) | Glucocorticoid-selektiv antiinflammatoriske midler | |
| YU87202A (sh) | Derivati arilmetilamina koji se koriste kao inhibitori triptaze | |
| DE69723863D1 (de) | Chinoline und deren therapeutische verwendung | |
| NZ513096A (en) | Compositions for treating inflammatory response | |
| DK1144365T3 (da) | Inhibitorer af alfa4beta1-medieret celleadhæsion | |
| MXPA02011858A (es) | Inhibidores de adhesion de celula mediada por alfabeta2. | |
| SI1492773T1 (sl) | 4-(heterociklil)-benzensulfoksiminske spojine za zdravljenje vnetja | |
| AP2000001761A0 (en) | Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase. | |
| MY128261A (en) | New substituted azetidinones as anti-inflammatory and antidegenerative agents | |
| AU4179399A (en) | Use of nmda antagonists and/or sodium channel antagonists for the treatment of inflammatory disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |